BDP9066 |
| Catalog No.GC33340 |
BDP9066은 강력하고 선택적인 근긴장성 이영양증 관련 Cdc42 결합 키나제 MRCK 억제제로, SCC12 세포에서 MRCKβ에 대해 IC50이 64nM이고, 하우스 측정에서 MRCKα/β에 대해 Ki 값이 각각 0.0136nM 및 0.0233nM입니다. BDP9066은 기질 인산화를 감소시켜 피부암에 치료 효과가 있습니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2226507-04-4
Sample solution is provided at 25 µL, 10mM.
BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinases MRCK inhibitor with an IC50 of 64 nM for MRCKβ in SCC12 cells, Ki values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation.
BDP9066 shows antiproliferative effects with greatest activity in hematologic cancer cells. BDP9066 inhibits MLC phosphorylation and blocks SCC12 squamous cell carcinoma motility and invasion[1].
BDP9066 topical application significantly decreases phosphorylated MRCKα S1003 staining and tumor volumes[1].
[1]. Unbekandt M, et al. Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin Cancer. Cancer Res. 2018 Apr 15;78(8):2096-2114.
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *